Status:
COMPLETED
The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
ALS Association
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures.
Eligibility Criteria
Inclusion
- El Escorial Classification of laboratory supported probable, probable,or definite ALS
- Age 18 - 80 years,
- ALS symptoms for no more than 3 years,
- FVC greater than or equal to 60% predicted,
- Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months,
- Patients must have the ability to attend monthly study visits in Edmonton or Calgary, Alberta
Exclusion
- Presence of significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness
- Female patients who are breastfeeding
- Use of concurrent investigational drugs,
- Patient unlikely to comply with study requirements
- Poor adherence to study protocol during run-in phase
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00409721
Start Date
March 1 2007
End Date
December 1 2010
Last Update
March 2 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Calgary ALS Neuromuscular Clinic
Calgary, Alberta, Canada, T2N 4N1
2
University of Alberta ALS Clinic
Edmonton, Alberta, Canada, T6G 2B7